Aardvark Therapeutics, Inc. Common StockAARD · SEC Filings
11.01 MFloat
1.35Price
29.54 MMarket Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
News
TYPE
HEADLINE
FILED AT
8-K
Exploratory ARD-101 data show modest hyperphagia reduction; FDA lifts clinical hold ahead of planned Phase 3 discussions and 2027 activities
8-K
FDA Lifts Clinical Hold on ARD-101, Allowing Potential Resumption of Prader-Willi Syndrome Development; Exploratory Trial Data Webcast Set for October 23
8-K
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
8-K
Aardvark Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders
8-K
Aardvark Therapeutics Reports Q2 2026 Financial Results and Provides ARD-101 Program Update
8-K
Aardvark Therapeutics Announces Retention Bonus Agreements for CFO/COO and CMO
